MarketPulse

phase 2 trial

7 articles
The Motley FoolThe Motley Fool··Lee Samaha

Ovid Therapeutics Surges 18% on Positive Phase 1 Data for OV329 Epilepsy Drug

Ovid Therapeutics surges 18% after Phase 1 data shows OV329 epilepsy drug eliminated safety concerns. Company secures $60M to fund Phase 2 trials.
OVIDbiotechprivate placement
BenzingaBenzinga··Vandana Singh

Pfizer's Breast Cancer Drug Hits Survival Goals as Oncology Pipeline Accelerates

Pfizer reports positive Phase 2 data for atirmociclib in metastatic breast cancer, meeting survival endpoints. Company also gains FDA approval for Braftovi in colorectal cancer.
PFEcolorectal cancerFDA approval
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Allarity Therapeutics Secures $20M Funding to Accelerate Stenoparib FDA Path

Allarity Therapeutics secures $20M non-dilutive debt financing to complete stenoparib Phase 2 trial and advance toward FDA approval, extending runway to mid-2028.
ALLRFDA approvaldebt financing
BenzingaBenzinga··Vandana Singh

Roche's Obesity Drug Falls Short of GLP-1 Rivals in Phase 2 Results

Roche's obesity drug petrelintide achieved 10.7% weight loss in Phase 2 trials but significantly trails GLP-1 rivals Novo Nordisk and Eli Lilly, triggering sharp stock declines.
LLYNVORHHBYclinical trial resultsweight loss
BenzingaBenzinga··Vandana Singh

Novo Nordisk's China Obesity Treatment Achieves 19.7% Weight Loss in Phase 2 Trial

Novo Nordisk's obesity drug UBT251 achieved 19.7% weight loss in Phase 2 trials for Chinese patients, offsetting recent setbacks from a failed competitor drug trial.
LLYNVOclinical trialweight loss
GlobeNewswire Inc.GlobeNewswire Inc.··Macrogenics, Inc.

MacroGenics Halts New Patient Enrollment in LINNET Trial Following FDA Clinical Hold

FDA places partial clinical hold on MacroGenics' LINNET trial due to serious adverse events including thrombocytopenia, myocarditis, and one death. New enrollment halted.
MGNXFDA clinical holdbispecific antibody
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Protara Therapeutics to Present TARA-002 Data at Major Medical Conferences

Protara Therapeutics will present TARA-002 Phase 2 interim data at ASCO GU Symposium, showcasing results for BCG-unresponsive bladder cancer treatment.
TARAinvestor conferencebladder cancer